Literature DB >> 25920483

Maternal deprivation disrupts mitochondrial energy homeostasis in the brain of rats subjected to ketamine-induced schizophrenia.

Alexandra Ioppi Zugno1, Felipe Damázio Pacheco, Josiane Budni, Mariana Bittencourt de Oliveira, Lara Canever, Alexandra Stephanie Heylmann, Patrícia Gomes Wessler, Flávia da Rosa Silveira, Gustavo Antunes Mastella, Cinara Ludwig Gonçalves, Karoline V Freitas, Adalberto Alves de Castro, Emilio L Streck, João Quevedo.   

Abstract

Maternal deprivation (MD) appears to be one of the environmental factors involved in the pathophysiology of schizophrenia. A widely used animal model of the schizophrenia involves the administration of ketamine, a dissociative anesthetic, NMDA receptors noncompetitive antagonist, that induce symptoms such as schizophrenia. To clarify the molecular mechanism of schizophrenia induced by MD, we investigated alterations in energetic metabolism, oxidative stress and neurotrophic factor levels in the brain of rats following MD and/or a single administration of ketamine during adulthood. Male Wistar rats were subjected to MD for 10 days. Additionally, these animals received acute ketamine (5, 15 or 25 mg/kg by intraperitoneal route, i.p.) during adulthood, and 30 min later, they were killed and the prefrontal cortex (PFC), the hippocampus and the striatum were removed for molecular analyses. Ketamine 25 mg/kg and/or MD and Ketamine 15 and 5 mg/kg with MD decreased the creatine kinase (CK) activity in the hippocampus. The enzyme activity of succinate dehydrogenase (SDH) in the Krebs cycle had increased in the striatum following the administration of ketamine 25 mg/kg, MD per se or MD plus ketamine 5 and 15 mg/kg. MD per se or MD combined with ketamine in different doses increased the activity of mitochondrial complexes. The PFC of animals subjected to MD and administered with ketamine 5 mg/kg exhibited increased protein carbonyl content. In the hippocampus, ketamine 15 mg/kg, ketamine 25 mg/kg and MD each increased the carbonyl content. In the striatum, the TBARS levels were increased by the administration of ketamine 25 mg/kg. Finally, in the hippocampus, MD alone or in combination with ketamine reduced the Nerve Growth Factor (NGF) levels; however, the Brain-derived Neurotrophic Factor (BDNF) levels were unaltered. In the present study, we suggest that MD increased the risk of psychotic symptoms in adulthood, altering different parameters of energy and oxidative stress. Our results suggest that adverse experiences occurring early in life may sensitize specific neurocircuits to subsequent stressors, inducing vulnerability, and may help us understand the pathophysiological mechanisms involved in this disorder.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25920483     DOI: 10.1007/s11011-015-9671-3

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  64 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

Authors:  A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

3.  The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia.

Authors:  Peng Xiong; Yong Zeng; Jing Wan; Diana Huang Xiaohan; Deyong Tan; Jin Lu; Fei Xu; Hong Yi Li; Zuxin Zhu; Mingxing Ma
Journal:  Psychiatry Res       Date:  2011-01-31       Impact factor: 3.222

4.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

Review 5.  Supramolecular structure of the mitochondrial oxidative phosphorylation system.

Authors:  Egbert J Boekema; Hans-Peter Braun
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

6.  Mitochondrial activity in the mapping of functional brain changes in schizophrenia.

Authors:  J A Prince; L Oreland
Journal:  Restor Neurol Neurosci       Date:  1998-06       Impact factor: 2.406

7.  Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport.

Authors:  A Cassina; R Radi
Journal:  Arch Biochem Biophys       Date:  1996-04-15       Impact factor: 4.013

Review 8.  Mitochondria, synaptic plasticity, and schizophrenia.

Authors:  Dorit Ben-Shachar; Daphna Laifenfeld
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

9.  Creatine kinase BB in brain in schizophrenia.

Authors:  Gulnur Sh Burbaeva; Olga K Savushkina; Irina S Boksha
Journal:  World J Biol Psychiatry       Date:  2003-10       Impact factor: 4.132

10.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

View more
  3 in total

Review 1.  Modeling mania in preclinical settings: A comprehensive review.

Authors:  Ajaykumar N Sharma; Gabriel R Fries; Juan F Galvez; Samira S Valvassori; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-11-04       Impact factor: 5.067

Review 2.  Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia.

Authors:  D A Maas; A Vallès; G J M Martens
Journal:  Transl Psychiatry       Date:  2017-07-18       Impact factor: 6.222

3.  Long-Term Effects of Maternal Deprivation on Redox Regulation in Rat Brain: Involvement of NADPH Oxidase.

Authors:  Branka Marković; Nevena V Radonjić; Gordana Jevtić; Tihomir Stojković; Milica Velimirović; Milan Aksić; Joko Poleksić; Tatjana Nikolić; Dubravka Aleksić; Vidosava Radonjić; Branislav Filipović; Nataša D Petronijević
Journal:  Oxid Med Cell Longev       Date:  2017-03-20       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.